United States Automated Compounding Devices Market: 11.4% CAGR to USD 6.19 Billion By 2033 | Major Companies - Grifols, S.A, Baxter International Inc, COMECER S.p.A., ARxIUM

The Global Automated Compounding Devices Market is set for significant expansion, growing from USD 2.35 billion in 2024 to USD 6.19 billion by 2033, registering an impressive CAGR of 11.4% during the forecast period (2025-2033).

The surge in demand is primarily driven by the growing need for precision medication compounding, the rising incidence of chronic diseases, and hospital initiatives toward enhancing patient safety through automation.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/automated-compounding-devices-market?ca

Recent developments include:

✅ In August 2025, Omnicell, Inc. announced an advanced upgrade to its IV compounding platform with integrated AI-based quality assurance, reducing manual verification time by 40%.
✅ In September 2025, Baxter International Inc. unveiled its next-generation ExactaMix Pro system, designed to support high-throughput TPN preparation across multi-site hospitals.
✅ In October 2025, ICU Medical, Inc. expanded its automated compounding solutions across major U.S. healthcare systems, emphasizing interoperability with electronic health records (EHRs).

The U.S. market is witnessing a strong push toward integrating robotics with cloud-based monitoring systems, ensuring real-time oversight of sterile compounding processes.

Recent Japanese market updates include:

✅ In August 2025, Grifols, S.A. entered a collaboration with Terumo Corporation to enhance automated IV compounding accuracy using gravimetric systems.
✅ In September 2025, COMECER S.p.A. launched its PharmaShield Series for Japanese oncology centers, offering integrated shielding and robotic precision.
✅ In October 2025, B. Braun Medical K.K. announced local production of semi-automated TPN devices to meet regional hospital demand.

Japan's focus on automation aligns with government-backed initiatives for pharmacy error reduction and sterile compounding compliance under its Good Compounding Practice (GCP) framework.

Industry Developments

✅ August 2025: Baxter International introduced an upgraded digital interface for its automated TPN systems, enhancing usability and error detection.

✅ September 2025: ARxIUM launched a service enhancement program offering predictive maintenance for hospital compounding robots in the U.S.

✅ September 2025: COMECER S.p.A. partnered with Japanese pharmaceutical facilities to deploy next-generation oncology compounding modules.

✅ October 2025: ICU Medical and Omnicell announced a joint pilot program integrating compounding and dispensing automation for major healthcare networks in North America.

✅ October 2025: EQUASHIELD expanded its closed-system transfer device integration with automated chemotherapy compounding systems.

Market Overview: Transforming Pharmacy Workflows through Automation

Automated compounding devices are increasingly redefining how hospital and clinical pharmacies prepare customized medications. These systems ensure precise dosing, minimize human error, and improve workflow efficiency, particularly in the preparation of intravenous (IV), chemotherapy, and total parenteral nutrition (TPN) formulations.

The rising prevalence of cancer and metabolic disorders has pushed healthcare institutions to adopt automated compounding systems that ensure accurate formulation and contamination-free processes. Additionally, government efforts to minimize medication errors and promote sterile compounding standards are accelerating market adoption.

In 2024, the market achieved a valuation of USD 2.35 billion, underpinned by a growing focus on healthcare digitization, an expanding hospital network, and the increasing integration of artificial intelligence and robotics in pharmaceutical operations.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=automated-compounding-devices-market?ca

Market Segmentation: Detailed Analysis by Product Type, Technology, Component, Mode of Operation, and End-User

By Product Type

The market for automated compounding devices is categorized into Intravenous (IV) Compounding Systems, Oral Liquid Compounding Systems, TPN Compounding Systems, and Chemotherapy Compounding Systems.

Among these, Intravenous (IV) Compounding Systems held the largest market share in 2024, valued at approximately USD 890 million, owing to their critical role in preparing sterile IV solutions in hospital pharmacies. The TPN Compounding Systems segment is projected to witness robust growth, supported by the increasing demand for parenteral nutrition among patients with gastrointestinal and metabolic disorders.

Meanwhile, Chemotherapy Compounding Systems are gaining attention due to the global rise in oncology cases, as these systems significantly reduce exposure risks for healthcare professionals. The Oral Liquid Compounding Systems segment, although smaller, is expanding steadily with the rise of pediatric and geriatric patient populations requiring customized dosage forms.

By Technology

Based on technology, the market is divided into Gravimetric Automated Compounding Devices, Volumetric Automated Compounding Devices, and Syringe-based Automated Compounding Devices.

Gravimetric technology dominated the market in 2024, accounting for nearly 45% of total revenue, due to its superior accuracy in weight-based measurements and enhanced quality assurance capabilities. Volumetric compounding systems continue to find applications in low-risk preparations, while syringe-based systems are increasingly used for small-volume chemotherapy and pediatric drug preparations.

By Component

The automated compounding ecosystem comprises Hardware, Software, and Services.

In 2024, Hardware components-including robotic arms, sensors, pumps, and precision scales-accounted for the majority of the market share, valued at around USD 1.15 billion. However, the Software segment is witnessing accelerated adoption, driven by cloud-based analytics and integration with hospital information systems (HIS).

Meanwhile, the Services segment is expected to expand at a steady CAGR as hospitals increasingly rely on maintenance contracts, calibration, and workflow training to ensure uninterrupted operation.

By Mode of Operation

The market is segmented into Fully Automated and Semi-Automated Compounding Devices.

In 2024, Fully Automated Systems led the market, capturing nearly 62% share, as hospitals prioritize precision, sterility, and labor efficiency. These systems eliminate manual intervention and improve traceability. Semi-Automated Systems remain relevant for small-scale facilities and developing regions, where budget constraints limit full automation adoption.

By End-User

End-users of automated compounding devices include Hospitals, Ambulatory Surgical Centers (ASCs), and Others such as research laboratories and compounding pharmacies.

Hospitals accounted for the dominant revenue share in 2024, estimated at USD 1.45 billion, as they represent the largest consumers of sterile compounding systems for parenteral nutrition and chemotherapy. The Ambulatory Surgical Centers segment is anticipated to grow rapidly during 2025-2033, driven by the increasing adoption of outpatient infusion services and the need for customized dosages.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/automated-compounding-devices-market?ca

Regional Insights: United States and Japan Driving Technological Leadership

United States

The U.S. Automated Compounding Devices Market remains a key revenue contributor, supported by robust healthcare infrastructure, regulatory compliance mandates, and a strong presence of leading market players. In 2024, the U.S. accounted for nearly 38% of the global market share, driven by widespread adoption in large hospital networks and oncology centers.

Japan

Japan represents one of Asia's most technologically progressive markets in automated compounding. The market is valued at USD 230 million in 2024, with growth driven by the aging population, rising chronic disease burden, and national initiatives to modernize hospital pharmacy operations.

Competitive Landscape: Leading Players Accelerating Innovation
The global automated compounding devices market features a mix of established multinational corporations and emerging technology-driven firms.

Grifols, S.A. continues to strengthen its presence through innovations in sterile IV compounding automation, leveraging its extensive pharmaceutical network across Europe and Asia.

Baxter International Inc. remains one of the market leaders, with a strong portfolio of TPN and IV compounding devices, supported by consistent product innovations and healthcare partnerships aimed at improving clinical efficiency.

COMECER S.p.A., a specialist in radiation shielding and aseptic processing systems, has been expanding into oncology-focused automated compounding solutions, emphasizing safety and contamination control.

ARxIUM is recognized for its RIVA platform-an advanced fully automated system for sterile drug preparation-which has gained adoption across leading hospitals in North America and Europe.

ICU Medical, Inc. focuses on end-to-end medication delivery systems that integrate compounding, infusion, and digital tracking. The company's continued investment in cloud-based automation is reshaping pharmacy operations globally.

Other notable players include Omnicell, EQUASHIELD, B. Braun Medical Inc., Becton, Dickinson and Company (BD), and SMARTCOMPOUNDERS B.V., each contributing to the diversification and technological sophistication of the market.

Future Outlook: Automation at the Core of Pharmacy Transformation
The global automated compounding devices market is entering a phase of rapid digital transformation. Integration of artificial intelligence, real-time monitoring, and Internet of Things (IoT) connectivity will redefine sterile compounding standards. As healthcare facilities worldwide aim for error-free, efficient, and compliant pharmacy operations, automated compounding devices are poised to become indispensable components of modern healthcare infrastructure.

With increasing R&D investments and the evolution of robotics and data-driven healthcare solutions, the industry's future outlook remains exceptionally strong, with global revenues expected to surpass USD 6.19 billion by 2033.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.